Stock Research for CRIS


Featured Broker: Ally Invest

Get the due diligence for another stock.


CRIS Stock Chart & Research Data

The CRIS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CRIS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CRIS Due diligence Resources & Stock Charts

The CRIS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CRIS Detailed Price Forecast - CNN Money CNN View CRIS Detailed Summary - Google Finance
Yahoo View CRIS Detailed Summary - Yahoo! Finance Zacks View CRIS Stock Research & Analysis -

Stock Analysis

TradeIdeas View CRIS Trends & Analysis - Trade-Ideas Barrons View CRIS Major Holders - Barrons
NASDAQ View CRIS Call Transcripts - NASDAQ Seeking View CRIS Breaking News & Analysis - Seeking Alpha
Spotlight View CRIS Annual Report - OTC Report View CRIS OTC Short Report -
TradeKing View CRIS Fundamentals - TradeKing Charts View CRIS SEC Filings - Bar Chart
WSJ View Historical Prices for CRIS - The WSJ Morningstar View Performance/Total Return for CRIS - Morningstar
MarketWatch View the Analyst Estimates for CRIS - MarketWatch CNBC View the Earnings History for CRIS - CNBC
StockMarketWatch View the CRIS Earnings - StockMarketWatch MacroAxis View CRIS Buy or Sell Recommendations - MacroAxis
Bullish View the CRIS Bullish Patterns - American Bulls Short Pains View CRIS Short Pain Metrics -

Social Media Mentions

StockTwits View CRIS Stock Mentions - StockTwits PennyStocks View CRIS Stock Mentions - PennyStockTweets
Twitter View CRIS Stock Mentions - Twitter Invest Hub View CRIS Investment Forum News - Investor Hub
Yahoo View CRIS Stock Mentions - Yahoo! Message Board Seeking Alpha View CRIS Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CRIS - Insider Cow View Insider Transactions for CRIS - Insider Cow
CNBC View CRIS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CRIS - OTC Markets
Yahoo View Insider Transactions for CRIS - Yahoo! Finance NASDAQ View Institutional Holdings for CRIS - NASDAQ

Stock Charts

FinViz View CRIS Stock Insight & Charts - StockCharts View CRIS Investment Charts -
BarChart View CRIS Stock Overview & Charts - BarChart Trading View View CRIS User Generated Charts - Trading View

Latest Financial News for CRIS

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Posted on Monday July 09, 2018

LEXINGTON, Mass., July 9, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on July 2, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 12,000 shares of Curis common stock to a new employee, with a grant date of July 2, 2018 (the "Q3 2018 Inducement Grant"). Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.  Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948.  CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene.  CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma.  Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

Benzinga Pro's 5 Stocks To Watch Today
Posted on Monday June 11, 2018

Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! NANO DIMENSION/S ADR (NASDAQ: NNDM ) stock was trading ...

Curis Shares Show Recent Gains, Pipeline Review and FDA Decision
Posted on Friday June 01, 2018

NEW YORK, NY / ACCESSWIRE / June 1, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Curis, Inc. (CRIS) is a biotechnology company, focused on the development and commercialization of drug candidates for the treatment of human cancers. Curis announced that its previously disclosed 1-for-5 reverse stock split will be effective as of 5:00 p.m. Eastern Time today, May 29, 2018. Curis's common stock will begin trading on the Nasdaq Global Market on a split-adjusted basis when the market opened on Wednesday, May 30, 2018.

Why Curis, Inc. Is Soaring Today
Posted on Thursday May 31, 2018

Traders cheer after the company reports upbeat regulatory news. Here's what investors need to know.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.